Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the unaudited financial results (standalone) of the Company for the quarter and half year ended 30th September 2026.

To, Dated: - October 21, 2026 The Manager, Department of Corporate Services, BSE Limited, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400001 Scrip Code: 539206 Symbol: GVBL Sub: Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, This is to inform you that the meeting of Board of Directors of the Company is scheduled to be held on Friday, 30th October, 2026 at the corporate office of the Company, inter-alia to transact the following business items with the permission of the Chair, if any: 1. To consider and approve the unaudited financial results (standalone) of the Company for the quarter and half year ended 30th September, 2026. 2. To consider any other matter with the permission of the chairman. Further, pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 read with Company’s code for prevention of Insider trading, the, “trading window” for dealing in securities of the Company is closed from October 01, 2026 until the end of 48 hours after the results are made public on October 30, 2026 for the Directors, KMPs, Promoters & Promoters Group and Designated Persons etc. covered under the code. Any other matter can be discussed with the permission of chair. This is for your information and record please. Thanking you. Yours sincerely, For Genomic Valley Biotech Limited Yogesh Agrawal Managing Director DIN: 01165288